For the first time, 36 world-leading institutions among European university hospitals, research centers, patient groups, non-profit product developers and pharmaceutical companies are coming together to shape the adaptive clinical trial platform of the future.The project, called EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL), is a unique public-private strategic partnership funded by the Innovative Medicines Initiative (IMI) to conceptualize and lead the design of an integrated research platform, enabling patient-centric drug development in Europe. Participants in EU-PEARL have the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), specifically for early development and focused on patients' interests, while seeking opportunities to address medical needs through the advancement of novel molecules. The EU-PEARL initiative intends to develop new methods, tools and frameworks to create a novel enabling infrastructure for conducting patient-centric platform trials through an integrated system where pharmaceutical companies, non-profit product developers and healthcare providers work together. The intent is to shape future clinical trials that will be more patient friendly by design and patient focused by outcome in four diseases areas: Major Depressive Disorder, Tuberculosis, Non-Alcoholic Steatohepatitis and Neurofibromatosis, and provide the framework for designing and executing IRPs in other disease areas.Traditional clinical trials versus platform trialsThe current model of evaluating one drug at a time in one trial often results in a long, sequential cycle of drug development, substantial investment and delays in getting the most effective treatments to patients. Competing trials challenge patient recruitment and patients often struggle to navigate the complex trial landscape to find the optimum clinical study.A platform trial is a clinical trial with a single master protocol in which multiple treatments are evaluated simultaneously. Adaptive platform designs offer flexible features such as removing a treatment group for futility or adding new groups and treatments to be tested during the course of the trial. The challenge of EU-PEARLDr. Joan Genescà, Head of the Hepatology Clinical Department of Vall d'Hebron Barcelona Hospital Campus and coordinator of the project, said: "We are facing an exciting near-term prospect: to be able to deliver medicines with a high molecular precision in a broad range of disease areas, within responsive and dynamic healthcare systems, and to facilitate a clinical decision-making process based on individual biological profiles and their response to therapies"."I am excited that together with pharmaceutical industry peers and public partners, we have a unique opportunity to collaborate in shaping clinical trials of the future", said Ann Van Dessel, Senior Vice President, Head Global Clinical Operations, Janssen Pharmaceutica NV. "Through this unique effort, we aim to establish and implement a patient-centric, future-focused framework to bring the most innovative medicines to people who need them as quickly as possible".The five pillars of EU-PEARLEU-PEARL is based on these pillars:The hospital hubs: The clinical network of hospitals will provide experienced environment for clinical trials and an ideal space to foster interaction of all stakeholders.The patients: EU-PEARL will foster an environment for patient engagement to play an important role in approaches to change the way clinical trials are conducted.Methods and Tools: EU-PEARL will develop an integrated set of methods and tools for the planning, implementation and analysis of adaptive platform trials.Regulatory framework: To provide the necessary standards to ensure that the collection and inclusion, processing and use of health and wellbeing data complies with European and national data protection and ethical regulations, regulatory requirements and legislation.Data governance: This project will also create the associated data governance ecosystem focusing on interoperability and quality of investigator/patient data, robust policies for access to global data and the creation of a governance structure for transparency, engagement and utilization.Supported by a grant from the IMIThis project has received funding from the Innovative Medicines Initiative 2 Join Undertaking under grant agreement No 853966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The total budget is 26M euros for a project duration of 42 months.EU-PEARL partnersThe 36 world-leading institutions that are part of EU-PEARL are: Vall d'Hebron Research Institute (VHIR) and Janssen Pharmaceutica NV, as coordinator and project leader respectively, EATRIS ERIC as co-coordinator and Novartis Pharma AG as co-project leader, and Synapse Research Management Partners as Executive Committee members.As receiving funding from IMI: Assistance Publique - Hospitaux de Paris, Berry Consultants LLP, Charité-Universitaets Medizin Berlin, Custodix (A TriNetX INC. Company), Documental OU, Erasmus Universitair Medisch Centrum Rotterdam, European Clinical Research Infrastructure Network (ECRIN), EUROSCAN International Network EV, Forum Europeen des Patients (FPE), King's College London, KU Leuven and University Psychiatric Center KU Leuven, Ludwig-Maximilians-Universitaet Muenchen, Medical University of Vienna, Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), The Chancellor Masters and Scholars of the University of Oxford, The European Institute for Innovation through Health Data, The University of Manchester, Università Degli Studi di Milano, Università Vita-Salute San Raffaele and University of Newcastle Upon Tyne.As in-kind contributors: Allergan Limited, Astrazeneca AB, Children's Tumor Foundation, Institut de Recherches Internationales Servier, Novo Nordisk A7S, Otsuka Novel Products GMBH, Pfizer Limited, Sanofi-Aventis Recherche & Development, SpringWorks Therapeutics Inc, TB Alliance and TEVA Pharmaceutical Industries Limited.